Related references
Note: Only part of the references are listed.
Article
Hematology
Brendan Beaton et al.
Summary: Patients with indolent lymphoma undergoing B cell suppression treatment are at risk of severe COVID-19. A study found that after receiving two doses of BNT162b2 vaccine, patients had lower levels of anti-spike IgG, which correlated with lymphocyte count and treatment time. However, all cohorts showed functional T cell responses.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Evangelos Terpos et al.
Article
Hematology
Julius C. Enssle et al.
Article
Hematology
Karthik Ramasamy et al.
Summary: Myeloma patients have poor immune responses to COVID-19 vaccination, with only a small percentage showing antibody and cellular immune responses. Male gender, anti-CD38/anti-BCMA therapy, and Pfizer-BioNTech vaccination are predicted to result in poor immune response.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article
Multidisciplinary Sciences
Bo Meng et al.
Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Medicine, General & Internal
Shabir A. Madhi et al.
Summary: The Omicron variant of SARS-CoV-2 spread more rapidly in South Africa, where two thirds of unvaccinated residents were found to have past infections. Omicron peaked just 1 month after being detected, with hospitalizations and deaths not increasing proportionately with the rise in cases. It remains unclear whether this change is due to widespread preexisting immunity or unique features of the virus.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Fabian Schmidt et al.
Summary: Neutralization assays showed much lower omicron neutralization compared to Wuhan-hu-1 after two doses of mRNA vaccine, but individuals who received a booster vaccine or were vaccinated after recovering from Covid-19 exhibited high levels of omicron neutralization.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Rolando Pajon et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Daniel Re et al.
Summary: Vaccination with a third dose of the mRNA vaccine BNT162b2 can boost immune response in patients with hematological malignancies, especially those who have shown response to the first two doses. However, it may not induce an antibody response in seronegative patients. This study highlights the importance of considering additional vaccine doses for patients with lymphoid malignancies to prevent severe COVID-19 symptoms.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Evangelos Terpos et al.
Summary: This study compared the neutralizing antibody levels after vaccination with BNT162b2 mRNA vaccine and ChAdOx1 (AZD1222) viral vector vaccine at different time points. The results showed that BNT162b2 induced stronger neutralizing antibody responses compared to AZD1222, and both vaccines showed a gradual decline in antibody titers over time. Additionally, the rate of antibody elimination was higher in those vaccinated with AZD1222 compared to BNT162b2. Age, gender, body mass index, or comorbidities did not significantly impact antibody levels over time.
Article
Hematology
Sabine Haggenburg et al.
Summary: Vaccination guidelines for hematological patients are typically conservative. However, this study shows that most patients, even those with compromised immune systems, can develop sufficient antibody concentrations after receiving the Moderna vaccine. However, certain treatments may affect the vaccine's efficacy.
Letter
Oncology
Robert Stuver et al.
Letter
Oncology
Adolfo Aleman et al.
Letter
Oncology
Julius C. Enssle et al.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After administering the fourth dose of BNT162b2 vaccine to individuals aged 60 years and older during the period when the omicron variant was predominant, Israel observed lower rates of confirmed SARS-CoV-2 infection and severe Covid-19 compared to those who received only three doses. The protection against severe illness remained consistent, while the protection against confirmed infection decreased over time.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Cristina Bergamaschi et al.
Summary: Immunocompromised individuals, such as patients with hematological malignancies, have a higher risk of severe disease after SARS-CoV-2 infection. Vaccination may provide limited protection in this population, and the reasons for reduced vaccine efficacy are not fully understood. This study compared the immune responses of patients who received bone marrow transplantation or CAR-T cells and healthy individuals after receiving two doses of the BNT162b2 mRNA vaccine. The results showed that the patients had significantly lower levels of SARS-CoV-2 Spike antibodies and reduced cross-recognition of different Spike-RBD proteins. The patients also exhibited diminished systemic cytokine responses compared to the healthy individuals. Changes in specific cytokines were associated with antibody development and could potentially be used as prognostic markers for vaccine effectiveness in transplant patients with hematological malignancies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Michel Obeid et al.
Summary: After vaccination with mRNA vaccines, the neutralizing antibody responses in immunocompromised patients and healthy controls have shown a decline at 6 months. These findings may provide insights for the development of optimal booster vaccination schedules, especially for immunocompromised patients.
Article
Immunology
Christian Gaebler et al.
Open Forum Infectious Diseases
(2022)
Letter
Medicine, General & Internal
Ria Lassauniere et al.
Letter
Medicine, General & Internal
Michael Klompas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Letter
Medicine, General & Internal
Panke Qu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Nicole P. Hachmann et al.
Summary: A small study found that omicron subvariants BA.2.12.1, BA.4, and BA.5 of SARS-CoV-2 were more likely to evade neutralizing antibodies induced by both vaccination and previous infection compared to the prior omicron subvariants BA.1 and BA.2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
John E. Bowen et al.
Summary: The Omicron variant of concern, characterized by numerous spike mutations, exhibits enhanced binding to ACE2, reduced fusogenicity, and reduced neutralizing activity against plasma induced by infection or vaccines. However, booster doses based on the Wuhan-Hu-1 spike sequence significantly increase neutralizing antibody titers and breadth against multiple Omicron sublineages.
Article
Immunology
Frances H. Priddy et al.
Summary: This prospective cohort study assessed the immune responses to BNT162b2 mRNA vaccine in New Zealand populations, with a focus on key populations at risk for COVID-19. The results showed robust antibody responses that were consistent with international data. Age and diabetes were associated with lower immune responses, while BMI was not. Neutralizing capacity against the Omicron BA.1 variant was severely diminished, but maintained against other variants of concern.
Article
Multidisciplinary Sciences
Li Wang et al.
Summary: Emerging SARS-CoV-2 variants may evade immune response, but COVID-19 mRNA vaccines still exhibit neutralizing activity against most variants.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Gianpaolo Marcacci et al.
Summary: This study demonstrates the safety and efficacy of sotrovimab as a post-exposure prophylaxis measure during the aplastic phase of autologous stem cell transplantation. It does not delay hemopoietic recovery and may be a valuable approach for high-risk patients exposed to highly infectious SARS-CoV-2 variants.
INFECTIOUS AGENTS AND CANCER
(2022)
Article
Oncology
Sabine Haggenburg et al.
Summary: This study aimed to assess the effectiveness of a third mRNA-1273 vaccination in immunocompromised patients with hematologic cancers. The results showed that a third vaccination had a significant effect in patients with recovering immune systems, but yielded poorer results in certain specific patient groups. Therefore, the administration of a third dose of vaccine should be considered in patients with hematologic cancers and evaluated on an individual basis.
Article
Cell Biology
Kirsten E. Lyke et al.
Summary: This study assesses the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. The results show that mRNA vaccine boosting generates higher neutralizing activity against the Omicron variant compared to Ad26.COV2.S boosting. These findings have implications for protecting against Omicron and future variants of SARS-CoV-2.
CELL REPORTS MEDICINE
(2022)
Letter
Hematology
Ioannis Ntanasis-Stathopoulos et al.
Article
Oncology
Sabine Haggenburg et al.
Summary: This study found that a third dose of mRNA-1273 vaccine can increase neutralizing antibody concentrations in immunocompromised patients with hematologic cancers, especially in those with recovering immune systems.
Letter
Oncology
Adolfo Aleman et al.
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The transmission of SARS-CoV-2 leads to the emergence of variants, such as the B.1.617.2 (Delta) variant, which dampens the in vitro potency of vaccine-elicited serum neutralizing antibodies. Mutations in the B.1.617.1 (Kappa) and Delta spike glycoproteins alter key antigenic sites, affecting the recognition by monoclonal antibodies. The angiotensin-converting enzyme 2 binding affinities of Kappa and Delta are comparable to the Wuhan-Hu-1 isolate, while Delta+ exhibits significantly reduced affinity.
Letter
Hematology
Evangelos Terpos et al.
Article
Medicine, General & Internal
Evangelos Terpos et al.
Summary: The study found that antibody responses against SARS-CoV-2 decreased over time, with Spike antibodies showing longer persistence. The antibody decay followed a biphasic trend, with more pronounced decrease in the first 6 months. The longevity and neutralizing ability of antibodies against Spike and Spike-RBD should be considered in future vaccination strategies.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Immunology
Margherita Rosati et al.
Summary: A study revealed that convalescent patients maintain robust antibody responses to SARS-CoV-2 for over a year after infection, providing long-lasting protection. The data showed that antibodies from convalescent patients persist over 14 months, continue to maintain cross-reactivity to current variants of concern, and exhibit strong functional properties.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Hematology
Heinz Ludwig et al.
Summary: Patients with multiple myeloma are at increased risk of infection and mortality related to SARS-CoV-2 virus, and may have suboptimal immune response to vaccination, highlighting the importance of monitoring and adapting vaccination strategies for this vulnerable population.
LANCET HAEMATOLOGY
(2021)
Article
Oncology
Evangelos Terpos et al.
Summary: Recent data shows suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Specifically, patients with multiple myeloma (MM) exhibit lower production of neutralizing antibodies (NAbs) after vaccination compared to healthy controls, especially when undergoing treatment with anti-CD38 or belamaf. Timely vaccination, possibly during treatment-free periods, is emphasized for this group of patients.
BLOOD CANCER JOURNAL
(2021)
Article
Cell Biology
Cristina Bergamaschi et al.
Summary: Early responses to vaccination play a crucial role in shaping both humoral and cellular protective immunity. This study characterizes cytokine and chemokine responses after the first and second dose of the BNT162b2 mRNA vaccine, highlighting the potential for biomarkers like IL-15 and IFN-gamma in predicting humoral immunity development. In previously COVID-19-infected individuals, a single vaccination can trigger strong cytokine induction and antibody responses similar to those seen in naive individuals upon booster vaccination, with implications for future public health recommendations.
Article
Hematology
Maria Gavriatopoulou et al.
Summary: Immunocompromised patients with hematologic malignancies, particularly those with Waldenstroeurom macroglobulinemia (WM), have lower production of neutralizing antibodies (NAbs) against SARS-CoV-2 after COVID-19 vaccination compared with healthy controls on days 22 and 50 post-vaccination. Disease-related immune dysregulation and therapy-related immunosuppression are likely contributors to this suboptimal humoral response. Active treatment with specific medications is also associated with a diminished antibody response following vaccination.
Article
Immunology
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Multidisciplinary Sciences
Davide F. Robbiani et al.
Article
Biotechnology & Applied Microbiology
Chee Wah Tan et al.
NATURE BIOTECHNOLOGY
(2020)
Article
Medicine, General & Internal
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Microbiology
Evangelos Terpos et al.
